ライフサイエンスコーパス: vitreous hemorrhage

1 R), vitrectomy was resorted for non clearing vitreous hemorrhage.

2 relation between rivaroxaban and spontaneous vitreous hemorrhage.

3 agulation may be associated with spontaneous vitreous hemorrhage.

4 sk of retinal detachment in fundus-obscuring vitreous hemorrhage.

5 compared with observation alone in eyes with vitreous hemorrhage.

6 Forty-eight patients had bilateral vitreous hemorrhage.

7 of contraction-promoting growth factors, or vitreous hemorrhage.

8 ntravitreous injection of Vitrase for severe vitreous hemorrhage.

9 ed with patient sex, age, or the presence of vitreous hemorrhage.

10 rhegmatogenous retinal detachment along with vitreous hemorrhage.

11 Retinal and vitreous hemorrhage.

12 adverse event from baseline to week 100 was vitreous hemorrhage (0.9% vs. 6.8% in the IAI 2Q4 + PRN

13 , temporary epithelial defect (1 [11%]), and vitreous hemorrhage (1 [11%]).

14 M (10 eyes), large exudative RD (4 eyes), or vitreous hemorrhage (1 eye).

15 age (1), central retinal vein occlusion with vitreous hemorrhage (1), and proliferative vitreoretinop

16 st frequent serious ocular adverse event was vitreous hemorrhage (1.3%, 0.7%, and 1.9%, respectively)

17 nts with epimacular proliferation (1.22) and vitreous hemorrhage (1.40) were also significantly eleva

18 quired vitreoretinal surgery for nonclearing vitreous hemorrhage, 1 in each 30 ms group; insignifican

19 More lasting complications included vitreous hemorrhage (2%), branch retinal artery obstruct

20 ed postmenstrual age (4 eyes, 30.8%); and/or vitreous hemorrhage (3 eyes, 23.1%).

21 resolving) included choroidal effusion (1), vitreous hemorrhage (3), Descemet detachment (1), and pe

22 66% (80%); neovascular glaucoma, 15% (22%); vitreous hemorrhage, 35% (42%); and secondary enucleatio

23 to have PFV (49%), Coats' disease (20%), or vitreous hemorrhage (7%); those 2 to 5 years of age were

24 Three patients developed spontaneous vitreous hemorrhage after initiating rivaroxaban anticoa

25 rom a young boy with a history of idiopathic vitreous hemorrhage and a female infant with familial ex

26 These included vitreous hemorrhage and inflammatory or infectious findi

27 biopsy can result in complications including vitreous hemorrhage and retinal detachment.

28 complications other than cataract included 2 vitreous hemorrhages and 2 retinal detachments.

29 mplete vascularization of peripheral retina, vitreous hemorrhage, and persistence of massive intravit

30 s after implant surgery, including cataract, vitreous hemorrhage, and retinal detachment, were relati

31 ear [EY]), the 3 most common being cataract, vitreous hemorrhage, and retinal detachment.

32 in the growth of fragile new blood vessels, vitreous hemorrhage, and retinal detachment.

33 included visual acuity, retinal detachment, vitreous hemorrhage, and secondary enucleation.

34 d to rule out vitreitis, retinal vasculitis, vitreous hemorrhage, and systemic amyloidosis.

35 ith NF1 and can cause exudative retinopathy, vitreous hemorrhage, and visual loss.

36 Vitreous hemorrhage at presentation was associated with

37 who presented with nontraumatic, nonsurgical vitreous hemorrhage between 2002 and 2012 were reviewed.

38 Only 1 of 57 eyes (1.8%) showed a transient vitreous hemorrhage, biopsy yield was 100% for genetic a

39 oup, but rates of retinopathy complications (vitreous hemorrhage, blindness, or conditions requiring

40 noblastomas include Coats' disease, PFV, and vitreous hemorrhage, but the spectrum varies depending o

41 cular hypertension, hemorrhagic retinopathy, vitreous hemorrhage, combined traction and rhegmatogenou

42 tachment, proliferative retinal disease, and vitreous hemorrhage contain varying amounts of growth fa

43 Vitreous hemorrhage density was scored using a 0 to 4 vi

44 The remaining 2 eyes had vitreous hemorrhage; endoscopic vitrectomy was done in t

45 edema, macular ischemia, foveal hemorrhage, vitreous hemorrhage, epiretinal membrane, and retinal de

46 Vitreous hemorrhage from diabetic neovascularization rem

47 Study eyes had vitreous hemorrhage from PDR precluding panretinal photo

48 ed with vitrectomy) compared with saline for vitreous hemorrhage from PDR that precludes placement or

49 rate of vitrectomy by 16 weeks in eyes with vitreous hemorrhage from PDR.

50 hemorrhage density was scored using a 0 to 4 vitreous hemorrhage grading scale in 12 radial segments

51 Spontaneous pediatric vitreous hemorrhage has a diverse etiology, vasculitis b

52 or the secondary surgery included persistent vitreous hemorrhage in 1.9% (14/739), rhegmatogenous ret

53 Postoperative complications included vitreous hemorrhage in 2 eyes, rhegmatogenous retinal de

54 ient ocular hypertension in 44 eyes (11.3%), vitreous hemorrhage in 31 eyes (7.9%), and transient hyp

55 permanent retinal detachment in 1 (7%), and vitreous hemorrhage in 4 (27%).

56 %), transient hypotony in 5 eyes (5.3%), and vitreous hemorrhage in 5 eyes (5.3%).

57 d retinopathy of prematurity may suffer from vitreous hemorrhage in the absence of retinal tears, det

58 embrane (n = 3), retinal hemorrhage (n = 2), vitreous hemorrhage (n = 1), retinal neovascularization

59 = 9) proliferative vitreoretinopathy (PVR), vitreous hemorrhage (n = 10), vitreous opacities (n = 8)

60 ina (n = 1); and had vitreous seeds (n = 3), vitreous hemorrhage (n = 2), retinal hemorrhage (n = 4),

61 stent fetal vasculature (PFV; n = 158; 28%), vitreous hemorrhage (n = 27; 5%), ocular toxocariasis (n

62 etic tractional retinal detachment (n = 49), vitreous hemorrhage (n = 40), full-thickness macular hol

63 rhage (n = 38), cataract (n = 16), resolving vitreous hemorrhage (n = 6), and eye pain (n = 5).

64 ude misplaced gas injection, subretinal gas, vitreous hemorrhage, new retinal breaks, failure to reat

65 ect a significant difference in incidence of vitreous hemorrhage, NVI, NVG, or need for vitrectomy.

66 Postoperative vitreous hemorrhage occurred in 16 patients (44%), but a

67 Recurrent vitreous hemorrhage occurred within 16 weeks in 6% and 1

68 phics, visual acuity, cause of "spontaneous" vitreous hemorrhage, ocular and systemic findings at pre

69 regression analysis revealed the presence of vitreous hemorrhage (odds ratio [OR], 7.29; P < 0.001),

70 anretinal photocoagulation, (4) experiencing vitreous hemorrhage, or (5) undergoing vitrectomy for th

71 ter injection was analyzed as a predictor of vitreous hemorrhage outcome at 3 months.

72 tion completion rates, and reduced recurrent vitreous hemorrhage rates suggest biologic activity of r

73 g outcome defined as the first occurrence of vitreous hemorrhage, retinal detachment, anterior segmen

74 reases in local growth factor expression, or vitreous hemorrhage, suggesting that other mechanisms ar

75 ed and refined to help prevent postoperative vitreous hemorrhage using cryotherapy around sclerotomy

76 eal bevacizumab (IVB) use in patients with a vitreous hemorrhage (VH) secondary to proliferative diab

77 ) undergoing pars plana vitrectomy (PPV) for vitreous hemorrhage (VH) with IVB pretreatment were pros

78 underwent pars plana vitrectomy (PPV): 6 for vitreous hemorrhage (VH), 1 for epiretinal membrane (ERM

79 resence of fibrovascular proliferation (FP), vitreous hemorrhage (VH), and tractional retinal detachm

80 proliferative diabetic retinopathy (PDR) and vitreous hemorrhage (VH).

81 A PPV was indicated in cases of nonresorbing vitreous hemorrhage (VH).

82 Permanent resolution of vitreous hemorrhage was achieved in 6 of 14 patients, an

83 detachment during the follow-up period, and vitreous hemorrhage was observed in 96.5% of cases (n =

84 ery and vitrectomy resulting from persistent vitreous hemorrhage was performed in 3.5% (n = 3) and 5.